Remdesivir Intermediate CAS 1770840-43-1 4-Amino-7-iodopyrrolo[2,1-f][1,2,4]triazine COVID-19
Manufacturer Commercial Supple Remdesivir et intermedia cum High Quality
Remdesivir CAS 1809249-37-3
2-Ethyl-1-butanol CAS 97-95-0
Trimethylsilyl Cyanide CAS 7677-24-9
4-Nitrophenol CAS 100-02-7
2-Ethylbutyl((S)-(perfluorophenoxys)(phosphoryl)-L-alaninatum CAS 1911578-98-7
N-[(S)-(4-nitrophenoxy) phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester CAS 1354823-36-1
(S)-2-Ethylbutyl 2-Aminopropanoate Hydrochloride CAS 946511-97-3
Remdesivir metabolitae (GS-441524) CAS 1191237-69-0
Remdesivir N-2 Intermedia CAS 1191237-80-5
2,3,5-Tri-O-benzyl-D-ribonolactone CAS 55094-52-5
7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine CAS 937046-98-5
Pyrrolo[1,2-F][1,2,4]Triazin-4-Amine CAS 159326-68-8
4-Amino-7-iodopyrrolo[2,1-f][1,2,4]triazine CAS 1770840-43-1
Nomen chemicum | 4-Amino-7-iodopyrrolo[2,1-f][1,2,4]triazine |
Synonyma | 7-Iodopyrrolo[2,1-f][1,2,4]triazin-4-amine;Remdesivir-004;Remdesivir immunditia 30 |
CAS Number | 1770840-43-1 |
CATTUS Number | RF-PI304 |
Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
Formulae hypotheticae | C6H5IN4 |
M. Pondus | 260.04 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Lux Yellow ut Brown pulveris |
Infrared Imaginis | Conformat ut Structure |
Puritas | ≥98.0% (HPLC) |
Damnum in Siccatio | ≤0.50% |
una immunditia | ≤0.50% |
Metalla gravis | ≤20ppm |
Test Standard | Enterprise Standard |
Consuetudinem | Intermedia Remdesiviri (CAS 1809249-37-3) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
4-Amino-7-iodopyrrolo[2,1-f][1,2,4]triazine (CAS 1770840-43-1) est medius Remdesivir (CAS 1809249-37-3).Remdesivir compositio antiviralis est quae actionem RNA polymeraseos inhibet.Remdesivir primum quaesitum est sicut curatio virus Ebola, sed potentia ad varias RNA virus tractandum habet.Eius actio contra coronavirus (CoV) familiae virus, ut SARS-CoV et MERS-CoV, anno 2017 descriptus est, et etiam explorata est ut curatio potentiae pro contagione SARS-CoV-2.